Direct Test Includes Eight Circulating Influenza Viruses
By LabMedica International staff writers Posted on 14 Jan 2015 |
Seasonal influenza epidemics occur primarily during the winter in temperate climates and year round in tropical climates and according to the experts, flu activity most commonly peaks in the United States between December and February.
A test kit with the eight additional influenza strains is now available directly and internationally. The test can report results in about an hour through a proprietary process that eliminates nucleic acid extraction, a time consuming technique typically employed by molecular tests.
The US Food and Drug Administration (FDA; Silver Springs, MD, USA) has granted 510(k) clearance to the test kit which is classified as Clinical Laboratory Improvement Amendments (CLIA) moderate complexity. The additional eight strains for which FDA cleared analytical reactivity are: H7N9, H3N2 (both the Minnesota and Indiana strains) as well as H1N1 (2011), H3N2 (the Ohio and Texas strains) and influenza B (Brisbane and Wisconsin strains). Of particular concern are the novel avian influenza A strain H7N9, which can cause death in as many as one third of infected patients, and the H3N2v, which infects humans more easily than other swine influenza virus.
The Simplexa Flu A/B & RSV Direct kit (Focus Diagnostics; Cypress, CA, USA) used with the 3M Integrated Cycler is a real-time polymerase chain reaction (RT-PCR) molecular test for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors.
Michelle Tabb, PhD, vice president of research and development for Focus Diagnostics, said, “Timely diagnosis is critical to effective management of infectious diseases like influenza. By providing fast, reliable results in about an hour, our Simplexa platform helps physicians quickly diagnose and treat patients. These changes to our Simplexa test reflect our vision to develop high quality molecular tests that deliver critical insights to improve outcomes and empower better health.”
Related Links:
US Food and Drug Administration
Focus Diagnostics
A test kit with the eight additional influenza strains is now available directly and internationally. The test can report results in about an hour through a proprietary process that eliminates nucleic acid extraction, a time consuming technique typically employed by molecular tests.
The US Food and Drug Administration (FDA; Silver Springs, MD, USA) has granted 510(k) clearance to the test kit which is classified as Clinical Laboratory Improvement Amendments (CLIA) moderate complexity. The additional eight strains for which FDA cleared analytical reactivity are: H7N9, H3N2 (both the Minnesota and Indiana strains) as well as H1N1 (2011), H3N2 (the Ohio and Texas strains) and influenza B (Brisbane and Wisconsin strains). Of particular concern are the novel avian influenza A strain H7N9, which can cause death in as many as one third of infected patients, and the H3N2v, which infects humans more easily than other swine influenza virus.
The Simplexa Flu A/B & RSV Direct kit (Focus Diagnostics; Cypress, CA, USA) used with the 3M Integrated Cycler is a real-time polymerase chain reaction (RT-PCR) molecular test for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors.
Michelle Tabb, PhD, vice president of research and development for Focus Diagnostics, said, “Timely diagnosis is critical to effective management of infectious diseases like influenza. By providing fast, reliable results in about an hour, our Simplexa platform helps physicians quickly diagnose and treat patients. These changes to our Simplexa test reflect our vision to develop high quality molecular tests that deliver critical insights to improve outcomes and empower better health.”
Related Links:
US Food and Drug Administration
Focus Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia